IDH, TP53, alpha-thalassemia/mental retardation, X-linked (ATRX) mutations, MGMTp methylation, and 1p/19q codeletion have been considered clinically meaningful markers of LGG (5–8), and especially IDH mutation, 1p/19q codeletion, and MGMTp methylation status are closely related to diagnosis and prognosis, which are crucial for postsurgical treatment such as adjuvant chemotherapy and adjuvant radiotherapy (9). The gene discussed is IDH2; the disease is alpha thalassemia spectrum.